// App-Quantinova.ai

P5-02-04 : Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study

Researchers

Presenter

  • Mieke Rosalie Van Bockstal

Principal Investigators

  • Serdar Altinay

  • Laurent Arnould

  • Noella Bletard

  • Cecile Colpaert

  • Franceska Dedeurwaerdere

  • Benjamin Dessauvagie

  • Valrie Duwel

  • Giuseppe Floris

  • Stephen Fox

  • Clara Gerosa

  • Shabnam Jaffer

  • Eline Kurpershoek

  • Magali Lacroix-Triki

  • Andoni Laka

  • Kathleen Lambein

  • Gatan Marie MacGrogan

  • Caterina Marchi

  • Dolores Martin Martinez

  • Sharon Nofech-Mozes

  • Dieter Peeters

  • Alberto Ravarino

  • Emily Reisenbichler

  • Erika Resetkova

  • Souzan Sanati

  • Anne-Marie Schelfhout

  • Vera Schelfhout

  • Abeer M Shaaban

  • Renata Sinke

  • Claudia Maria Stanciu-Pop

  • Claudia Stobbe

  • Carolien HM van Deurzen

  • Koen Van de Vijver

  • Anne-Sophie Van Rompuy

  • Stephanie Verschuere

  • Anne Vincent-Salomon

  • Hannah Wen

  • Caroline Bouzin

  • Christine Galant

Medical Centers

  • SSS/IREC/RUMA, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium

  • University of Health Sciences Bakirköy, Istanbul, Turkey

  • Center Georges-Francois Leclerc, Dijon, France

  • CHU de Liège - site Sart Tilman, Liège, Belgium

  • GZA-ZNA Hospitals, Antwerp, Belgium

  • AZ Delta, Roeselare, Belgium

  • University of Western Australia, Crawley, Australia

  • AZ Klina, Brasschaat, Belgium

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • University Hospital of Cagliari, Cagliari, Italy

  • Mount Sinai Hospital/Icahn School of Medicine, New York, NY

  • Pathan, Rotterdam, Netherlands

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Clinique Notre-Dame de Grâce, Gosselies, Belgium

  • AZ St Lucas Hospital, Ghent, Belgium

  • Department of Biopathology, Institut Bergonié, Bordeaux, France

  • University of Turin and Pathology Unit, Torino, Italy

  • Curepath, Jumet, Belgium

  • Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada

  • AZ St. Maarten, Mechelen, Belgium

  • Yale University School of Medicine/Yale New Haven Hospital, New Haven, CT

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Washington University School of Medicine, St. Louis, MO

  • Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium

  • Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom

  • CHU UCL de Mont-Godinne, Yvoir, Belgium

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • University Hospital Gent, Gent, Belgium

  • Pôle de Médicine Diagnostique & Théranostique, INSERM U934, Institut Curie, Paris, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Institute of Clinical and Experimental Research, Brussels, Belgium

Locations

  • Belgium

  • Turkey

  • France

  • Australia

  • Italy

  • United States

  • Netherlands

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved